Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST StudyMedicine Published on 2021-06-092022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 95% CI Analysis association C-reactive protein conditions COVID-19 COVID-19 patient COVID-19 patients Cox proportional-hazards model darunavir death death rate drugs finding Hospitalized hospitals hypertension in-hospital mortality increased mortality increased risk inhibitor Italian Italian patient Kidney disease large cohort less limit Lopinavir Lopinavir/ritonavir Measures medical records men Mortality outcome Patient patients Probability receiving risk SARS-CoV-2 severity of COVID-19 Support therapeutic agent These data three groups Treatment Weighting women [DOI] 10.3389/fmed.2021.639970 PMC 바로가기 [Article Type] Medicine
QT Interval Monitoring with Handheld Heart Rhythm ECG Device in COVID-19 PatientsCOVID-19 환자에서 휴대용 심장 리듬 ECG 장치를 사용한 QT 간격 모니터링Observational Study Published on 2021-06-082022-09-11 Journal: Global Heart [Category] SARS, 임상, 진단, 치료제, [키워드] 6-lead ECG addressed adverse effect Azithromycin baseline Cohort control group COVID-19 COVID-19 patient Device displaying dissemination ECG evaluate evaluated feasibility feasible Follow-up groups handheld ECG healthcare providers healthy heart Hospitalization Hydroxychloroquine ICC increase in interval KardiaMobile KardiaMobile-6L Lopinavir Lopinavir-ritonavir moderate monitoring no differences not differ offer patients Prospective Prospective Study QTc QTC prolongation receiving reliability rhythm Ritonavir significantly significantly lower smart device Therapies time treated ventricular arrhythmia virus was performed [DOI] 10.5334/gh.916 PMC 바로가기 [Article Type] Observational Study
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study분자 도킹 연구를 이용한 SARS-CoV-2 주요 단백질 분해 효소의 잠재적 억제제 식별에 대한 조사Article Published on 2021-06-012022-09-11 Journal: Journal of biomolecular structure & dynamics [Category] Coronavirus, SARS, 치료제, [키워드] active site acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affecting anti-fungals anti-viral drug anti-virals approach blind catalytic caused clinical trial clinical trials coronavirus Cys145 drug Efficiency Emetine followed by GLN189 Glu166 Gly143 Health Organization hesperidin highest HIS163 HIS164 His41 identify in vitro in vivo include Indinavir Infectious disease inhibitor inhibitors inhibitors of SARS-CoV-2 Lopinavir molecular molecular docking molecules MPro natural products nematodes new strain pandemic protease residue residues Ritonavir rutin SARS-CoV-2 SARS-CoV-2 main protease SARS-CoV-2 Mpro SARS-CoV-2 protease severe acute respiratory syndrome Coronavirus the SARS-CoV-2 Treatment viral replication virus WHO World Health Organization [DOI] 10.1080/07391102.2020.1763201 PMC 바로가기 [Article Type] Article
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia중등도에서 중증 SARS-CoV-2 폐렴에서 Favipiravir의 안전성 및 효능Randomized Controlled Trial Published on 2021-06-012022-09-11 Journal: International immunopharmacology [Category] 임상, 치료제, [키워드] 95% CI Adding addition changes in Chest chest computerized tomography scan clinical clinical recovery clinical trial Computerized tomography COVID19 CT scan deaths did not reduce Efficacy enrolled examined Favipiravir ground glass group groups Hospital mortality Hospital stay Hydroxychloroquine ICU admission ICU admissions in-hospital mortality Infection intubation intubations less Lopinavir Lopinavir/ritonavir mean hospital stay moderate moderate to severe Mortality multicenter not different not significantly different oxygen oxygen saturation Patient Pneumonia quantified Randomized Randomly regimen Ritonavir Safety SARS-CoV-2 Severe case severe SARS-CoV-2 standard care supplemental oxygen time Treatment Treatment protocol treatment regimen treatment regimens two groups [DOI] 10.1016/j.intimp.2021.107522 PMC 바로가기 [Article Type] Randomized Controlled Trial
Plant-derived chemicals as potential inhibitors of SARS-CoV-2 main protease (6LU7), a virtual screening studySARS-CoV-2 주요 프로테아제(6LU7)의 잠재적 억제제로서의 식물 유래 화학물질, 가상 스크리닝 연구Comparative Study Published on 2021-06-012022-09-11 Journal: Phytotherapy research : PTR [Category] Coronavirus, SARS, 치료제, [키워드] 3CLpro 6LU7 active site active sites ADMET antiviral activity antiviral properties antiviral property binding energy caused Compound compounds coronavirus disease Coronavirus disease 2019 COVID-19 cysteine cysteine protease dataset deaths docking Ebola Emetine enzyme Ginkgolide HIV Infection inhibitor inhibitors inhibitors of SARS-CoV-2 Lopinavir Mezerein molecular molecular docking MPro nelfinavir pharmacological physicochemical property phytochemicals protease SARS-CoV-2 shown Taking target Tubocurarine Virtual screening viruses Vitexin was performed was selected was used were used Zika [DOI] 10.1002/ptr.7041 PMC 바로가기 [Article Type] Comparative Study
Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations전염병에 대한 화학 예방 실험 설계: COVID-19 연구 등록에 대한 체계적인 검토에서 얻은 통찰력Review Published on 2021-05-292022-09-10 Journal: Trials [Category] SARS, 변종, 치료기술, 치료제, [키워드] adaptive adaptive design Adaptive platform trial Adults alignment Analysis attack rate attack rates Care Chain Reaction Chemoprophylaxis Chloroquine clinically collaboration component control group coronavirus country COVID-19 COVID-19 vaccines database detect effect size effective Efficacy Efficacy and safety eligibility enrolment Epidemic Epidemics epidemiologically Evidence evidence of exit feasible feature focus followed by General population generate healthcare worker Healthcare workers Hydroxychloroquine implementation Infection Infectious disease Infectious diseases information International IQR less Long-term care Lopinavir Lopinavir/ritonavir mechanism median median size novel vaccines offer Older older adult Older adults pandemic patients polymerase chain reaction Polymerase chain reaction testing PrEP Primary outcome Prophylaxis protocol provided public health randomised Rapid recruitment Registered Repurposed drug Repurposed drugs required Result review Ritonavir robust safety analysis SARS-CoV-2 screened searched Serological testing study population supplementary material Supporting systematic review target population Trial trial infrastructure Trial registration trials utility Vaccine Vaccines virus variants was used were assessed widespread without symptom [DOI] 10.1186/s13063-021-05323-4 PMC 바로가기 [Article Type] Review
Outcomes of patients with end stage kidney disease on dialysis with COVID-19 in Abu Dhabi, United Arab Emirates; from PCR to antibody아랍에미리트 아부다비에서 코로나19 투석을 받은 말기 신장질환 환자의 결과; PCR에서 항체로Research Published on 2021-05-262022-09-01 Journal: BMC Nephrology [Category] SARS, 진단, 치료제, [키워드] Abu addition age antibody Antibody Response Antibody responses Asymptomatic average average age camostat characteristics of patient Cohort combinations Community Comorbidities concerning Contact contributed cough country COVID 19 COVID-19 COVID-19 infection COVID19 Critical care defined demographics develop diabete diabetes dialysis disease drug End stage kidney disease examined family Favipiravir Haemodialysis heart disease Hydroxychloroquine hypertension ICU IgG antibody individual infected individual infected individuals Infection Ischaemic heart disease Isolation Kidney disease lack Local Lopinavir lower mortality majority male median time Mild Mild disease Mortality Most patients negative PCR test outcome overall mortality Patient patients PCR PCR positive patient PCR positivity PCR tests performed Population positive patient positive patients presenting symptoms Rapid required Result Ritonavir Screening screening strategy serology source of infection spread of COVID-19 steroid Steroids study period subset symptomatic tested the antibody response Tocilizumab Viral viral clearance was performed were used with COVID-19 [DOI] 10.1186/s12882-021-02378-y PMC 바로가기 [Article Type] Research
Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients로피나비르/리토나비르 및 하이드록시클로로퀸을 사용한 치료는 COVID-19 환자의 급성 신장 손상과 관련이 있습니다Research Article Published on 2021-05-112022-09-10 Journal: PLoS ONE [Category] SARS, 치료제, [키워드] Acute kidney injury acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Affect AKI Analysis analyzed Antiviral agents both groups Care control group controls coronavirus coronavirus disease correlation COVID-19 COVID-19 patient COVID-19 patients creatinine CYP3A4 cytochrome P450 enzyme Germany Hospitalized Hydroxychloroquine ICU ICU patient ICU Patients in both group in vitro activity incidence increase in independent risk factor Interaction Kidney function Kidney injury linear linear correlation Lopinavir Lopinavir/ritonavir mechanism Mortality National Early Warning Score NEWS non-ICU non-ICU patients P450 Patient patients R 2 receiving respiratory Result Ritonavir SARS-CoV-2 score serum creatinine severe acute respiratory syndrome Coronavirus severely ill COVID-19 patients severity severity of illness Standard therapy therapy treated Treatment treatment of COVID-19 university university hospital was performed with COVID-19 [DOI] 10.1371/journal.pone.0249760 PMC 바로가기 [Article Type] Research Article
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study코로나19 환자의 용도 변경 및 보조제 사용: 다국적 네트워크 코호트 연구Research Published on 2021-05-112022-09-10 Journal: The BMJ [Category] Fulltext, SARS, 신약개발, [키워드] antagonists Antibiotics Azithromycin benefit ceftriaxone China cohort study common Corticosteroid Corticosteroids COVID-19 pandemic declined Dexamethasone drug Electronic health record Electronic health records enoxaparin FIVE H2 receptor hospital Hospital admission Hydroxychloroquine in hospital patient Lopinavir LOPINAVIR AND RITONAVIR Lopinavir-ritonavir management Multiple objective outcome measure pandemic participant Patient prescription Prescriptions receptor antagonists remained Repurposed drug Repurposed drugs Result risk Ritonavir setting South Korea Spain The United States Treatment umifenovir United States Variation Vitamin D were used [DOI] 10.1136/bmj.n1038 PMC 바로가기 [Article Type] Research
In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel—A Drug AntitargetCardiovascular Medicine Published on 2021-05-042022-10-31 Journal: Frontiers in Cardiovascular Medicine [Category] COVID-19, [키워드] abnormality absence Antitarget Antiviral antiviral drug antiviral treatments approach aromatic residue arrhythmia Atazanavir binding binding pockets binding site canonical Combination component computational modeling Contact COVID-19 cryo-EM structure determinant docked domain drug drugs ECG exploration Favipiravir FIVE hERG human ether-à-go-go–related gene in silico include inhibit Interaction less Lopinavir Lopinavir-ritonavir Pore potassium channel Potential reduced Remdesivir residue residues risk Ritonavir SARS-CoV-2 structure-function torsades de pointe Treatment [DOI] 10.3389/fcvm.2021.645172 PMC 바로가기 [Article Type] Cardiovascular Medicine